About KNSA
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arter... [Read more]
Industry Biotechnology
Sector Healthcare
IPO Date May 24, 2018
Employees 297
Stock Exchange NASDAQ
Ticker Symbol KNSA
Full Company Profile
Financial Performance
In 2023, KNSA's revenue was $270.26 million, an increase of 22.74% compared to the previous year's $220.18 million. Earnings were $14.08 million, a decrease of -92.32%.
Financial Statements
Analyst Forecast
According to 5 analysts, the average rating for KNSA stock is "Strong Buy." The 12-month stock price forecast is $30.2, which is an increase of 58.53% from the latest price.
Price Target
$30.2
(58.53% upside)
Analyst Consensus: Strong Buy
Stock Forecasts
News
Kiniksa Pharmaceuticals to Present at Bank of America Securities 2024 Health Care Conference
HAMILTON, Bermuda, May 07, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Bank of America Securities 2...
17 days ago - GlobeNewsWire
Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio Execution
– ARCALYST ® (rilonacept) Q1 2024 net product revenue of $78.9 million, representing 85% year-over-year growth – – ARCALYST 2024 expected net product revenue increased to $370 - $390 million – – Abipr...
4 weeks ago - GlobeNewsWire
Kiniksa Pharmaceuticals to Report First Quarter 2024 Financial Results on April 23, 2024
HAMILTON, Bermuda, April 16, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, April 23, 2024 at 8:...
5 weeks ago - GlobeNewsWire
Kiniksa Pharmaceuticals Announces Development Indication for Abiprubart
– Abiprubart Phase 2b trial in Sjogren's Disease planned to initiate in 2H 2024 – – Abiprubart Phase 2 Cohort 4 rheumatoid arthritis data further validate biological activity – – Abiprubart developmen...
7 weeks ago - GlobeNewsWire
Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Portfolio Execution
– ARCALYST ® (rilonacept) Q4 2023 and full-year 2023 net product revenue of $71.2 million and $233.2 million, respectively –
3 months ago - GlobeNewsWire
Kiniksa Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024
HAMILTON, Bermuda, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Wednesday, February 28, 2024 a...
3 months ago - GlobeNewsWire
Kiniksa Pharmaceuticals Provides Corporate Update
– ARCALYST ® (rilonacept) 2023 net product revenue grew ~90% year-over-year to $233.1 million (unaudited) –
5 months ago - GlobeNewsWire
Kiniksa Pharmaceuticals to Present at 42nd Annual J.P. Morgan Healthcare Conference
HAMILTON, Bermuda, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 42nd Annual J.P. Morgan Healthcare Conference onMonday, J...
5 months ago - GlobeNewsWire
Kiniksa Pharmaceuticals Reports Third Quarter 2023 Financial Results and Recent Portfolio Execution
– ARCALYST ® (rilonacept) Q3 2023 net product revenue of $64.8 million, representing ~94% year-over-year growth –
7 months ago - GlobeNewsWire
Kiniksa Pharmaceuticals to Report Third Quarter 2023 Financial Results on October 31, 2023
HAMILTON, Bermuda, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, October 31, 2023 at 8...
7 months ago - GlobeNewsWire
Kiniksa Pharmaceuticals Reports Second Quarter 2023 Financial Results and Recent Portfolio Execution
– ARCALYST ® (rilonacept) Q2 2023 net product revenue of $54.5 million – – ARCALYST 2023 net product revenue guidance increased to $220 - $230 million, representing ~84% year-over-year growth at the m...
10 months ago - GlobeNewsWire
Kiniksa Pharmaceuticals to Report Second Quarter 2023 Financial Results on July 25, 2023
HAMILTON, Bermuda, July 17, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, July 25, 2023 at 8:30...
11 months ago - GlobeNewsWire
Kiniksa Pharmaceuticals to Present at Goldman Sachs 44th Annual Global Healthcare Conference
HAMILTON, Bermuda, June 06, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that management will participate in a fireside chat at the Goldman Sachs 44th Annual G...
1 year ago - GlobeNewsWire
Kiniksa Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent Portfolio Execution
– ARCALYST ® (rilonacept) Q1 2023 net product revenue of $42.7 million – – ARCALYST full-year 2023 net product revenue guidance increased to $200 - $215 million, representing ~69% year-over-year growt...
1 year ago - GlobeNewsWire
Kiniksa Pharmaceuticals to Report First Quarter 2023 Financial Results on May 2, 2023
HAMILTON, Bermuda, May 01, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, May 2, 2023, at 8:30 a...
1 year ago - GlobeNewsWire
Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Portfolio Execution
– ARCALYST ® (rilonacept) Q4 2022 and full-year 2022 net product revenue of $39.9 million and $122.5 million, respectively –
1 year ago - GlobeNewsWire
Kiniksa Pharmaceuticals to Report Fourth Quarter and Full-Year 2022 Financial Results on February 28, 2023
HAMILTON, Bermuda, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, February 28, 2023, at...
1 year ago - GlobeNewsWire
Kiniksa Pharmaceuticals to Present at 41st Annual J.P. Morgan Healthcare Conference
HAMILTON, Bermuda, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 41st Annual J.P. Morgan Healthcare Conference onMonday, J...
1 year ago - GlobeNewsWire
Kiniksa Pharmaceuticals to Present at Bank of America Securities 2022 Biotech SMID Cap Conference
HAMILTON, Bermuda, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that management will participate in a fireside chat atthe Bank of America Securities ...
1 year ago - GlobeNewsWire
Kiniksa Pharmaceuticals to Present at Evercore ISI 5th Annual HealthCONx Conference
HAMILTON, Bermuda, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that management will participate in a fireside chat atthe Evercore ISI 5th Annual Hea...
1 year ago - GlobeNewsWire
Kiniksa Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
– ARCALYST ® (rilonacept) Q3 2022 net revenue of $33.4 million – – RHAPSODY long-term extension data demonstrated rilonacept treatment beyond 18 months resulted in continued treatment response (Hazard...
1 year ago - GlobeNewsWire
Kiniksa Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 1, 2022
HAMILTON, Bermuda, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, November 1, 2022, at ...
1 year ago - GlobeNewsWire
Kiniksa Pharmaceuticals Announces Closing of Global License Agreement with Genentech for Vixarelimab
HAMILTON, Bermuda, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company with a portfolio of assets designed to modulate immunological ...
1 year ago - GlobeNewsWire
Kiniksa Pharmaceuticals to Present at 2022 Wedbush PacGrow Healthcare Conference
HAMILTON, Bermuda, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that its management will participate in a fireside chat atthe 2022 Wedbush PacGrow He...
1 year ago - GlobeNewsWire
Kiniksa Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
– ARCALYST ® (rilonacept) net revenue of $27.0 million in Q2 2022 –
1 year ago - GlobeNewsWire
